Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18348934 | 0.79 | HMGCR (0.36) | — | |
| SCHEMBL7582452 | 0.79 | PRKCA (0.46) | PRKCAELANE | |
| SCHEMBL1142628 | 0.79 | PRKCA (0.41) | PRKCANPSR1ELANE | |
| SCHEMBL10335296 | 0.79 | PRKCA (0.41) | PRKCAPOLBGAANPSR1ELANE | |
| SCHEMBL2691885 | 0.77 | CA12 (0.43) | PRKCAPOLBGAANPSR1 | |
| SCHEMBL12076232 | 0.77 | ALOX15 (0.44) | PRKCAPOLBGAANPSR1ELANE | |
| SCHEMBL14175340 | 0.76 | PRKCA (0.47) | PRKCAPOLBGAANPSR1ELANE | |
| SCHEMBL15121417 | 0.76 | PRKCA (0.39) | PRKCAPOLBGAANPSR1ELANE | |
| SCHEMBL25891695 | 0.76 | PRKCA (0.47) | PRKCAPOLBGAANPSR1ELANE | |
| SCHEMBL19742312 | 0.75 | PRKCA (0.41) | PRKCAPOLBGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444696-B1 | 1-ARYL OR HETEROARYL SUBSTITUTED 5-AMINO-4 CARBONYLPYRAZOLE DERIVATIVES; ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) LLC | 2002-09-03 | — | — | US | claimed |
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-08-01 | — | — | US | claimed |
| EP-1218346-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-03 | — | — | EP | claimed |
| US-6316466-B1 | Pyrazole derivatives P-38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | claimed |
| WO-2001021591-A1 | PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-03-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | MAPK1, MAPK8, MAPKAPK2 | PRKCA 47/4885POLB 2374/4885GAA 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.